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Abstract
Background: Lack of standardisation for the measurement of exhaled nitric oxide (NO) (FE ) has resulted in conflicting dataNO
in cystic fibrosis (CF). The aim of this study was to assess whether FE is a useful non-invasive marker of lung disease in CFNO
by assessing the effect of intravenous (IV) antibiotics on FE . Methods: FE was measured on line, according to recentlyNO NO
published ERSyATS guidelines, using a chemiluminescence analyser together with pulmonary function in 14 CF children prior to
and following a course of IV antibiotics. Results: There was a significant improvement in mean (S.E.M.) % FEV from 60.01
(6.3) to 68.0 (5.4) (P-0.05) and mean (S.E.M.) % FVC from 66.3 (5.5) to 75.1 (4.9) (P-0.01). FE increased significantlyNO
from median (range) 5.8 (2.0–14.3) to 9.2 ppb (0.8–25.1) (P-0.05). There was no correlation between FE and lung function.NO
Subgroup analysis on those with chronic Pseudomonas aeruginosa infection (ns6) demonstrated no significant change in FE .NO
Conclusions: Using a flow of 50 mlys, FE increases following admission for IV antibiotic treatment in children with CF butNO
does not correlate with lung function. It is not a useful marker of lung diseases in CF, which has implications for clinical practice.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide (NO) is involved in a number of impor-
tant physiological processes within the lung, including
inflammation w1x. In the past few years there has been
an increase in the development of exhaled nitric oxide
(FE ) as a non-invasive marker for inflammatory lungNO
diseases such as asthma, cystic fibrosis (CF) and bron-
chiectasis w2x. FE is surprisingly low in CF, consid-NO
ering the degree of inflammation present in the lower
airway. While some studies have shown that FE inNO
CF is similar to healthy children w3–7x other studies
have demonstrated significantly lower levels w8–11x.
Further, while some studies have suggested that FENO
correlates with lung function w5,12x, others have not
w10,13x. These discrepancies may partly arise due to
lack of standardisation of the measurement of FE . InNO
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an attempt to overcome this, the ATS and ERS joint
task force have recently published guidelines for the
measurement of FE in children w2,14x. The aim ofNO
this study was to investigate whether FE is a usefulNO
non-invasive marker of lung disease in CF by assessing
the effect of intravenous (IV) antibiotics on FE andNO
lung function in children with CF using these latest
recommendations.
2. Subjects and methods
Children with CF were studied following routine
admission to Great Ormond Street Hospital for Children
for a course of IV antibiotics. Those commenced on
steroids during the admission were excluded. FE andNO
spirometry were measured on admission and prior to
discharge. FE measurements were performed accord-NO
ing to current ERSyATS guidelines using a dedicated
chemiluminescence analyser (NIOX, Aerocrine, Swe-
den) by the single breath on-line method prior to lung
function w2x. Seated subjects inhaled NO free air to total
lung capacity and exhaled for 10 s through a flow
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Fig. 1. FE before and after IV antibiotics.NO
regulator at 50 mlys using visual feedback. The 3-s
plateau was recorded automatically by dedicated soft-
ware and an average of three acceptable values was
recorded. The equipment detected FE from -1 toNO
200 parts per billion (ppb) with a response time of 200
ms. Pulmonary function was then measured according
to ATS guidelines (Masterscreen, Jaeger, Germany)
w15x. Sputum samples or cough swabs were cultured on
admission. Measurements before and after treatment
were compared by Wilcoxon signed ranks test. The
Mann–Whitney U-test was used to compare those chron-
ically infected with Pseudomonas aeruginosa (P. aeru-
ginosa) to those not infected. Chronic infection was
defined as culture of the organism on two or more
occasions in the 6 months prior to the study w16x.
Spearman correlation tests were used to assess correla-
tion of FE with lung function parameters. A value ofNO
P-0.05 was considered significant. Results are
expressed as median (range) or mean (standard error of
mean (S.E.M.)).
3. Results
Fifteen CF subjects were recruited but one was
excluded because oral steroids were commenced on
admission. Fourteen CF subjects (10 female), median
age (range) 12.1 years (5.9–16.0) were studied. The
median (range) length of treatment was 8.5 (6–15)
days. Genotypes were as follows: DF508yDF508, ns
10; DF508yN1303K, ns1; DF508y-, ns3. Reasons for
admission were: infective exacerbation, ns4; routine
quarterly antibiotics, ns10. Cough swab or sputum
culture on admission were as follows: P. aeruginosa,
ns6; Staphylococcus aureus, ns6 (one patient had
coliform species and another had Stenotrophomonas
maltophilia in addition); no growth, ns2. Nebulised
antibiotics were stopped on admission, as is routine
clinical practice in our department. Two subjects were
on regular inhaled steroids and nine subjects were on
recombinant human DNAse therapy.
There was a significant improvement in mean
(S.E.M.) percent predicted forced expiratory volume in
1 s(FEV %) from 60.0 (6.3) (range 28–99) to 68.01
(5.4) (range 34–95) (P-0.05). The percent predicted
forced vital capacity (FVC%) increased significantly
from a mean (S.E.M.) 66.3 (5.5) (range 42–103) to
75.1 (4.9) (range 43–105) (P-0.01). Following IV
antibiotic treatment there was a significant increase in
FE from median (range) 5.8 ppb (2.0–14.3) to 9.2NO
ppb (0.8–25.1) (P-0.05) (Fig. 1). Subgroup analysis
on those with chronic P. aeruginosa infection (ns6)
demonstrated no significant change in FE followingNO
IV antibiotic treatment. Furthermore, there was no cor-
relation between lung function values in either those
chronically infected with P. aeruginosa and in those not
infected (Fig. 2).
4. Discussion
This study has shown that admission for IV antibiotics
increases both lung function and FE . There is noNO
correlation between these two parameters. The levels of
FE , both before and after antibiotics in our study areNO
lower than those measured in healthy children using the
same technique w17x and support previous observations
in CF subjects w3–11x. NO is synthesised from L-
arginine by constituitive (cNOS) and inducible (iNOS)
isoforms of NO synthase and little is known about the
relative contribution of these isoforms to FE . Inflam-NO
matory cells such as neutrophils abundantly express
iNOS. Because inflammatory cytokines and bacterial
products upregulate iNOS and contribute to neutrophilic
influx into the airways it would be reasonable to expect
high levels of FE in CF.NO
One reason for reduced FE may be that the expres-NO
sion of iNOS in bronchial epithelium is reduced in CF
w18x. However, the increase in FE following IVNO
antibiotics in our study suggests that this is not the sole
cause of low NO as iNOS expression would be expected
to be downregulated following antibiotic treatment due
to a reduction in both bacterial load and pro-inflamma-
tory cytokines. Furthermore, nitrates and nitrites, the
end products of metabolism of NO, are increased in CF
suggesting that NO is rapidly metabolised at the site of
production in the lower airway w6,19,20x. A possible
explanation for both this increase in NO metabolites and
for reduced FE comes from Jones et al. who demon-NO
strated that superoxide production by activated neutro-
phils reacts with NO forming nitrate and peroxynitrite.
w21x
Another potential cause for low FE has beenNO
suggested by Gaston et al. who demonstrated that both
sputum ex vivo and P. aeruginosa in vitro consumed
NO, probably due to the presence of NO reductase in P.
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Fig. 2. The relation of all values of pulmonary function to FE (a) Without P. aeruginosa. (b) Chronically infected with P. aeruginosa.NO
aeruginosa w22x. This was supported by the observation
that tobramycin treatment of sputum inhibited NO con-
sumption due to an anti-pseudomonal effect. This mech-
anism may explain the earlier suggestions that low
FE in CF was due to ‘trapping’ of NO in sputum w3x.NO
The same group demonstrated a significant increase
in FE in 14 adult CF subjects chronically infectedNO
with P. aeruginosa following treatment with IV antibi-
otics. Six subjects had FE measurements made on-NO
line by a similar method to our study. They demonstrated
a small but significant increase from 3.4 to 5.0 ppb,
which was attributed to a possible reduction in NO
reductase produced by the bacterium. These results are
similar to that seen in our study. However, we did not
detect a change in FE in those six subjects chronicallyNO
infected with P. aeruginosa, which may reflect the small
sample size. In addition, although eight subjects in our
study did not have P. aeruginosa cultured from cough
swab or sputum on admission, all subjects had previ-
ously grown P. aeruginosa but did not fulfil the criteria
for chronic infection w16x. It is possible that some
subjects had P. aeruginosa present in the lower airway,
which was not cultured on this occasion. Importantly,
there was no difference between the two groups at the
commencement of the study (Table 1).
Our study has shown an increase in FE followingNO
IV antibiotic treatment, which is in disagreement with 2
previous studies. Ho et al. measured the effect of a 7-
day course of IV antibiotics in eight adult CF subjects
and demonstrated no change using a single breath on
line technique with an exhalation flow of 250 mlys. w5x
Using a similar technique, with an exhalation flow of
200 mlyminute, Jobsis et al. demonstrated no change in
FE in six CF children following IV treatment w13x.NO
However, in these studies, the flows for measuring
FE were different from the current guidelines of 50NO
mlys (3lymin). It is known that the rate of exhalation
is crucial in the single breath on-line technique, as
FE is inversely proportional to expiratory flow w9,23xNO
and these discrepancies make comparisons between
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Table 1
Summary of CF subject characteristics. There were no significant differences between both groups
Infected with P. aeruginosa Not infected with P. aeruginosa
Total number 6 8
Number of females 3 7
Age 14.3 10.1
(decimal age median (range)) (6.2–15.5) (5.9–16.0)
Genotype all DF508 4 DF508, 3 DF508yy, 1 DF508yN1303K
Treatment length 9.5 8.5
(median days (range)) (6–15) (6–15)
FVC on admission 68 65
(mean (S.E.M.)) (9.9) (7.2)
FVC at discharge 70.8 78.4
(mean (S.E.M.)) (10.3) (5.2)
FEV on admission1 63.7 57.3
(mean (S.E.M.)) (13.0) (7.1)
FEV at discharge1 65.5 69.9
(mean (S.E.M.)) (11.6) (5.6)
NO on admission 8.6 4.7
(median (range)) (2.0–14.3) (3.8–10.4)
NO at discharge 14.8 8.8
(median (range)) (0.8–25.1) (2.6–15.6)
studies difficult. It has been suggested that, in diseases
with an airway component, lower flows may be a better
discriminator of disease from well states w2x.
This lack of standardisation may also account for the
varying results from studies attempting to correlate
FE with lung function. In two studies, Ho et al. foundNO
a significant correlation of FEV with FE in CF1 NO
subjects w5,12x using flows of 250 mlys. Grasemann et
al. found a significant correlation of FE with FVCNO
but not FEV in CF subjects using single breath on-line1
measurements with a sampling flow of 25 mlys but no
control for exhalation flow w8x. We found no correlation
in our study which is in agreement with two previous
studies using exhalation flows of 200 mlys w10,13x.
There are some limitations to our study. Due to lack
of an appropriate control group, it is unclear whether
the increase in FE is attributable to IV antibioticsNO
alone or due to sputum clearance by physiotherapy,
mucolytics or a combination of therapies. The ideal
control group would be CF subjects admitted for phys-
iotherapy only. However, for obvious reasons, this was
not practical. An out-patient control group was deemed
unsatisfactory as adherence to therapies, such as physi-
otherapy, is likely to be poorer than during an in-patient
hospital stay. w24x Further, we did not investigate the
effect of other sputum clearing mechanisms such as
recombinant human DNase on FE . The specific effectNO
of sputum clearance on FE is an area for furtherNO
research.
Another potential limitation of our study is the inclu-
sion of subjects on regular inhaled steroids (ns2)
because it is known that steroids reduce FE in CFNO
patients w25x. We excluded one subject who was com-
menced on oral steroid treatment during admission.
Inhaled steroids are used widely (up to 93% in some
UK centres) w26x and we included subjects on inhaled
steroids to reflect clinical practice. Interestingly, despite
inhaled steroids, both subjects demonstrated an increase
in FE following admission for IV antibiotics (7.5 toNO
15.6 ppb, 3.8–5.0 ppb). This further supports our
suggestion that the low FE in CF is not solely due toNO
downregulation of iNOS expression.
We undertook all measurements at least 4 h following
treatment with b agonists because of previous studies
suggesting that bronchodilators may affect FE w12x.NO
While most subjects had FE measured at approxi-NO
mately 11 h, it was difficult to measure FE at exactlyNO
the same time of day for all subjects because of local
infection control policies. However, preliminary work
suggests that there is no diurnal variability in FENO
measured by the identical technique used in our study
w17x. Nevertheless, despite these limitations, we believe
that from a practical point of view, FE is not a usefulNO
marker of lung disease for a child with CF. As a result
of this study, our practice has changed in that we no
longer undertake routine FE measurements in childrenNO
with CF as part of lung function assessment.
In conclusion, using the latest ERSyATS guidelines
we have demonstrated that FE is low in children withNO
CF, in agreement with previous studies. FE increasesNO
following admission for IV antibiotic treatment in chil-
dren with CF, suggesting that the low FE values inNO
CF are not solely due to a down-regulation of iNOS in
lung epithelium. Furthermore, using a flow of 50 mlys,
FE does not correlate with lung function. It is not aNO
useful marker of lung diseases in CF, which has impli-
cations for clinical practice.
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